A Randomized, Open-Label, Multi-Center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-Operative Therapy in Patients With High Risk Localized Breast Cancer.

Trial Profile

A Randomized, Open-Label, Multi-Center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-Operative Therapy in Patients With High Risk Localized Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Larotaxel (Primary) ; Docetaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms SATIN
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Dec 2010 Actual end date changed from Mar 2010 to Aug 2010 as reported by ClinicalTrials.gov.
    • 22 Nov 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top